March 21, 2017 | Esperion Therapeutics says the Food and Drug Administration has agreed that the company's medicine, bempadoic acid, could be approved based on blood test results, before a larger study proving it prevents heart attacks, strokes, heart procedures, or deaths has been completed. Forbes